BamSEC and AlphaSense Join Forces
Learn More

Mersana Therapeutics Inc.

NASDAQ: MRSN    
Share price (1/7/25): $1.37    
Market cap (1/7/25): $169 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 6 pages December 19, 2024 Mersana Therapeutics, Inc. 840 Memorial Drive Cambridge, Ma 02139 Re: Section 3(a)(9) Exchange Agreement Ladies and Gentlemen
12/34/56
EX-10.43
from 10-K 3 pages Mersana Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy as Amended Through December 15, 2023
12/34/56
EX-10.24
from 10-K 7 pages July 20, 2021 via E-Mail
12/34/56
EX-10.5
from 10-Q 7 pages Via Electronic Mail September 6, 2023 Arvin Yang Dear Arvin
12/34/56
EX-10.4
from 10-Q 15 pages Mersana Therapeutics, Inc. 840 Memorial Dr. Cambridge, Ma 02139 September 5, 2023 via Electronic Delivery
12/34/56
EX-10.3
from 10-Q 12 pages Retirement and Separation Agreement
12/34/56
EX-10.2
from 10-Q 5 pages Amendment No. 2 to Research Collaboration and License Agreement
12/34/56
EX-10.1
from 10-Q 4 pages Amendment No. 1 to the Research Collaboration and License Agreement by and Between Mersana Therapeutics, Inc. and Janssen Biotech, Inc
12/34/56
EX-10.3
from 10-Q 2 pages Mersana Therapeutics, Inc. 2017 Stock Incentive Plan Restricted Stock Unit Agreement
12/34/56
EX-10.2
from 10-Q 4 pages Mersana Therapeutics, Inc. 2017 Stock Incentive Plan Restricted Stock Unit Agreement
12/34/56
EX-10.1
from 10-Q 4 pages Mersana Therapeutics, Inc. 2022 Inducement Stock Incentive Plan Restricted Stock Unit Agreement
12/34/56
EX-10.7
from 10-Q 5 pages Agreement Regarding Licr Technology
12/34/56
EX-10.6
from 10-Q 49 pages License, Development and Commercialization Agreement Between Mersana Therapeutics, Inc. and Recepta Biopharma S.A
12/34/56
EX-10.5
from 10-Q 6 pages Amendment 3 to Collaboration and Commercial License Agreement
12/34/56
EX-10.4
from 10-Q 5 pages Amendment 2 to Collaboration and Commercial License Agreement
12/34/56
EX-10.3
from 10-Q 5 pages Amendment 1 to Collaboration and Commercial License Agreement
12/34/56
EX-10.2
from 10-Q 74 pages Collaboration and Commercial License Agreement Between Mersana Therapeutics, Inc. and Merck Kgaa
12/34/56
EX-10.42
from 10-K 3 pages Mersana Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
12/34/56
EX-10.40
from 10-K 11 pages Mersana Therapeutics, Inc. 2017 Employee Stock Purchase Plan
12/34/56
EX-10.21
from 10-K 4 pages Agreement
12/34/56